CENTOGENE Reports Full Year 2022 Financial Results
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 16, 2023 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq:CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2022, and provided a business update.
Related news for (CNTG)
- CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
- CENTOGENE Receives French Research Tax Credit Accreditation
- CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
- CENTOGENE Announces Preliminary Full Year 2023 Revenue